Attached files
file | filename |
---|---|
10-K/A - AIM ImmunoTech Inc. | v182822_10ka.htm |
EX-32.1 - AIM ImmunoTech Inc. | v182822_ex32-1.htm |
EX-31.2 - AIM ImmunoTech Inc. | v182822_ex31-2.htm |
EX-31.1 - AIM ImmunoTech Inc. | v182822_ex31-1.htm |
Exhibit
32.2
CERTIFICATION
PURSUANT TO
18
U.S.C. SECTION 1350,
AS
ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the Annual Report of Hemispherx Biopharma, Inc. (the “Company”)
on Form 10-K/A for the fiscal year ended December 31, 2009 as filed with the
Securities and Exchange Commission on the date hereof (the “Report”), I, Charles
T. Bernhardt, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002,
that:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the
Company.
/s/ Charles T.
Bernhardt
|
||
Charles
T. Bernhardt CPA
|
||
Chief
Financial Officer
|
||
April
30, 2010
|
1